Bruce Mann
#90,437
Most Influential Person Now
Oncologist
Bruce Mann 's AcademicInfluence.com Rankings
Bruce Mann philosophy Degrees
Philosophy
#12014
World Rank
#16623
Historical Rank
Logic
#8830
World Rank
#11098
Historical Rank
Download Badge
Philosophy
Bruce Mann 's Degrees
- Doctorate Medicine Harvard University
- PhD Biomedical Sciences Stanford University
Why Is Bruce Mann Influential?
(Suggest an Edit or Addition)According to Wikipedia, Gregory Bruce Mann is an Australian surgical oncologist. He is the Director of Breast Cancer Services at the Royal Women's Hospital in Melbourne, Australia, the largest specialist women's care hospital in Australia.
Bruce Mann 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. (2013) (255)
- A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. (1995) (236)
- RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers (2016) (217)
- The Lymphatic Anatomy of the Breast and its Implications for Sentinel Lymph Node Biopsy: A Human Cadaver Study (2007) (215)
- Targeting lymphangiogenesis to prevent tumour metastasis (2006) (163)
- Adjuvant therapy in gastric cancer. (2005) (158)
- Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. (2005) (147)
- Predictors of Surgical Margin Status in Breast-Conserving Surgery Within a Breast Screening Program (2008) (115)
- Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma (2001) (114)
- Molecular Detection of Micrometastatic Breast Cancer in Histopathology-Negative Axillary Lymph Nodes Correlates With Traditional Predictors of Prognosis: An Interim Analysis of a Prospective Multi-Institutional Cohort Study (2004) (107)
- A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. (2018) (80)
- A single‐cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast (2021) (74)
- Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma (2012) (73)
- Does the Extent of Operation Influence the Prognosis in Patients With Melanoma Metastatic to Inguinal Nodes? (1999) (70)
- Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months (2013) (70)
- Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. (2010) (70)
- The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer (2013) (63)
- Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome (2015) (60)
- Gastrointestinal stromal tumour treated with neoadjuvant imatinib (2005) (58)
- An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic (2020) (58)
- Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features (2017) (57)
- Adult soft tissue sarcoma. (1999) (55)
- Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond. (2013) (54)
- Carbon localisation of impalpable breast lesions. (2003) (53)
- Sentinel lymphatic mapping in breast cancer. (1999) (48)
- Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer (2017) (47)
- Spotlight on the utility of the Oncotype DX® breast cancer assay (2018) (44)
- Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis (2013) (44)
- Endocrine Surgeon-Performed US Guided Thyroid FNAC is Accurate and Efficient (2012) (42)
- Copy number analysis of ductal carcinoma in situ with and without recurrence (2015) (42)
- Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. (2009) (40)
- Women's reflections on fertility and motherhood after breast cancer and its treatment. (2014) (40)
- Assessing and managing breast cancer risk: clinicians' current practice and future needs. (2014) (40)
- Reoperative sentinel lymph node biopsy in ipsilateral breast cancer relapse. (2009) (35)
- Six-Year Follow-Up of Patients With Microinvasive, T1a, and T1b Breast Carcinoma (1999) (34)
- Emerging role of laparoscopy in the diagnosis of lymphoma. (1998) (33)
- iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management (2016) (31)
- Patient-reported outcomes in ductal carcinoma in situ: A systematic review. (2017) (30)
- Comparison of blue dye and isotope with blue dye alone in breast sentinel node biopsy (2005) (30)
- Benign Papilloma on Core Biopsy Requires Surgical Excision (2008) (29)
- Comparison of Outcomes After Laparoscopic Versus Posterior Retroperitoneoscopic Adrenalectomy: A Pilot Study (2014) (29)
- Laparoscopic or open appendicectomy for suspected appendicitis in pregnancy and evaluation of foetal outcome in Australia (2017) (28)
- Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer. (2014) (28)
- Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis (2013) (27)
- Alternative sites of injection for sentinel lymph node biopsy in breast cancer (2003) (27)
- Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. (2016) (26)
- Fertility Management After Breast Cancer Diagnosis: A Qualitative Investigation of Women's Experiences of and Recommendations for Professional Care (2013) (25)
- Posterior retroperitoneoscopic adrenalectomy: outcomes and lessons learned from initial 50 cases (2015) (22)
- “A Natural Progression”: Australian Women's Attitudes About an Individualized Breast Screening Model (2019) (20)
- POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes (2018) (20)
- Profile and Predictors of Long-term Morbidity in Breast Cancer Survivors (2013) (20)
- Consumer and clinician perspectives on personalising breast cancer prevention information. (2019) (19)
- Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women (2018) (18)
- The Prognostic Impact of Isolated Tumor Cells in Lymph Nodes of T2N0 Gastric Cancer: Comparison of American and Japanese Gastric Cancer Patients (2009) (18)
- Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease? (2016) (17)
- Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma (2019) (17)
- Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. (2016) (17)
- Colorimetric histology using plasmonically active microscope slides (2021) (17)
- Solitary pituitary metastasis from HER2‐positive breast cancer (2017) (15)
- Molecular Detection of Micrometastatic Breast Cancer in Histopathology—Negative Axillary Lymph Nodes Fails to Predict Breast Cancer Recurrence: A Final Analysis of a Prospective Multi-Institutional Cohort Study (2010) (15)
- Maternal breast cancer and communicating with children: A qualitative exploration of what resources mothers want and what health professionals provide. (2019) (15)
- Factors influencing reoperation following breast‐conserving surgery (2018) (14)
- Follow-up of Women with Early Stage Breast Cancer (2014) (14)
- Laparoscopic creation of pericardial window. (1994) (12)
- Molecular comparison of interval and screen‐detected breast cancers (2019) (12)
- Improving breast cancer screening in Australia: a public health perspective. (2019) (11)
- Study protocol for Enhancing Parenting In Cancer (EPIC): development and evaluation of a brief psycho-educational intervention to support parents with cancer who have young children (2017) (11)
- Meta‐analysis of techniques for closure of midline abdominal incisions (Br J Surg 2002; 89: 1350–1356) (2003) (11)
- The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing (2018) (11)
- The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma (2020) (10)
- Outcomes of Screening-Detected Ductal Carcinoma In Situ Treated with Wide Excision Alone (2011) (10)
- Five‐year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer (2013) (10)
- The impact and indications for Oncotype DX on adjuvant treatment recommendations when third‐party funding is unavailable (2018) (9)
- Axillopectoral muscle: An important anomaly in axillary surgery (2005) (9)
- Do All Patients Require Radiotherapy after Breast-Conserving Surgery? (2010) (8)
- The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma (2020) (8)
- Report of the Eleventh International Symposium of the Foundation for Promotion of Cancer Research: Basic and Clinical Research in Gastric Cancer. (1998) (8)
- Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. (2017) (8)
- Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery. (2021) (8)
- Sentinel node biopsy in breast cancer revisited. (2014) (8)
- Angiosarcoma arising in an unirradiated breast with subsequent pituitary metastasis. (2007) (8)
- Identification of germ-line chimaeras by polymerase chain reaction and isoenzyme analysis of mouse spermatozoa. (1993) (8)
- Management of Early Node‐Positive Breast Cancer in Australia: A Multicentre Study (2016) (7)
- Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS) (2021) (7)
- Uptake of adjuvant breast cancer treatments recommended by multi‐disciplinary meetings (2018) (7)
- Predictors of outcome after surgery for gastric cancer in a Western cohort (2016) (7)
- Valuing preferences for treating screen detected ductal carcinoma in situ. (2019) (6)
- Linkage of the murine transforming growth factor alpha gene with Igk, Ly-2, and Fabp1 on chromosome 6. (1993) (6)
- Fasciitis ossificans with a radial neuropathy: A benign differential diagnosis for soft tissue sarcoma (2007) (6)
- Insights into the physiology of TGF alpha and signaling through the EGF receptor revealed by gene targeting and acts of nature. (1994) (5)
- Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma in Situ (DCIS) of the Breast in a Randomized Clinical Trial (SweDCIS) (2021) (5)
- A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer (2016) (5)
- Breast Cancer Survivor Symptoms: A Comparison of Physicians' Consultation Records and Nurse-Led Survivorship Care Plans. (2020) (5)
- Breast conservation versus mastectomy in triple-negative breast cancer: two steps forward, one step back? (2011) (4)
- The role of magnetic resonance imaging in early breast cancer (2012) (4)
- Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low‐grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR) (2022) (4)
- Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC) (2019) (4)
- Feasibility of Enhancing Parenting in Cancer, a psychoeducational intervention for communicating with children about parental cancer (2021) (3)
- Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result (2019) (3)
- Methods for Evaluating Medical Tests and Biomarkers (2017) (3)
- Surgeon knows best versus breast cancer surgical clinical trial equipoise: a plea for the sake of future trials (2017) (3)
- Multicentre evaluation of magnetic technology for localisation of non‐palpable breast lesions and targeted axillary nodes (2021) (2)
- Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma (2012) (2)
- Small bowel malignancy: an elusive diagnosis (2004) (2)
- SO05 THE NATURE OF NEARBY LYMPHATICS DICTATES WHETHER A VASCULAR ENDOTHELIAL GROWTH FACTOR‐D (VEGF‐D) INDUCES TUMOR LYMPHATICS AND METASTASIS (2007) (2)
- Window of opportunity treatment in breast cancer (2019) (2)
- Abstract P5-15-02: Indications for, and impact of oncotype DX on adjuvant treatment recommendations when third party funding is unavailable (2016) (2)
- Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer (2020) (2)
- The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort (2020) (1)
- A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy. (2022) (1)
- Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis (2012) (1)
- Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features. (2021) (1)
- The Breast Service psychosocial model of care project. (2009) (1)
- ASO Author Reflections: Impact of Breast Cancer Screening Beyond Mortality Reductions (2018) (1)
- Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women (2018) (1)
- Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review (2023) (1)
- Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care (2023) (1)
- Abstract S2-04: RANK ligand as a target for breast cancer prevention inBRCA1mutation carriers (2017) (1)
- Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis (2013) (1)
- Gastric cancer (2004) (1)
- Abstract P5-03-02: Expression of RANK and RANK ligand (RANKL) in breast carcinoma and distinct breast epithelial cells from BRCA1 mutation carriers (2013) (1)
- Mammography Adherence among High-Risk Women with Breast Cancer and Either a Non-Pathogenic Mutation Identified or Untested BRCA1/2 Genetic Status (2020) (1)
- Outcomes of women at high familial risk for breast cancer: An 8‐year single‐center experience (2020) (1)
- Universal genetic testing of patients with newly diagnosed breast cancer — ready for prime time? (2021) (1)
- Erratum to: Methods for evaluating medical tests and biomarkers (2017) (0)
- Re-Thinking Clinicopathologic Risk Assessment in DCIS: Pooled Data from Validation Studies Comparing a 7-gene DCIS Assay to Clinicopathologic Features Alone (2022) (0)
- Abstract P5-01-07: Recruitment, clinical equipoise, patient acceptance and compliance in the UK-ANZ POSNOC trial (2023) (0)
- Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study (2021) (0)
- Clinical utility of routine parathyroid hormone measurement in women commenced on endocrine therapy for hormone sensitive breast cancer (2020) (0)
- Abstract P5-09-01: Neoadjuvant hormonal therapy plus palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer (2023) (0)
- Neoadjuvant chemotherapy in non-metastatic breast cancer: The surgeon's perspective. (2023) (0)
- Impact of Laparoscopy in Malignant Lymphomas (2002) (0)
- Abstract P3-09-02: Mutational assessment of newly diagnosed breast cancer using Germline and tumor genomICs (2022) (0)
- Treatment Intensity Differences According to Participation in a Population Screening Program (2019) (0)
- Abstract B016: Guiding de-escalation of treatment for patients with DCIS using a predictive 7-gene biosignature: Identification of a clinically low-risk patient group (2022) (0)
- Contrast enhanced mammography in breast cancer surveillance. (2022) (0)
- BS07 MEDIUM‐TERM OUTCOME OF SCREEN‐DETECTED DCIS TREATED WITH WIDE EXCISION ALONE (2009) (0)
- Assessment of the Likelihood of Invasive Breast Cancer When Core Needle Biopsy Shows DCIS. (2009) (0)
- Abstract PD9-01: Prospect trial MRI findings: High incidence of occult cancers in apparently low risk cases (2020) (0)
- Abstract OT3-11-03: The PREDICT Registry Australia: A prospective registry to evaluate the clinical utility of a 7-gene predictive biosignature on treatment decisions in patients with ductal carcinoma in situ (2023) (0)
- Utility of stromal lymphocytes in diagnosis and predicting upgrade of B3 breast lesions from core biopsies (2022) (0)
- Status of sentinel node biopsy - response. (2015) (0)
- Abstract PD15-07: PD15-07 7-gene predictive biosignature improves risk stratification for breast ductal carcinoma in situ patients compared to clinicopathologic criteria, identifying a low risk group not clinically benefiting from adjuvant radiotherapy (2023) (0)
- Abstract P1-04-06: Characterization of recurrence risk after lumpectomy and radiotherapy in HER2-positive ductal carcinoma in situ of the breast, using 7-gene predictive biosignature: Implications for the NSABP-B43 trial results (2023) (0)
- Surgery - a pillar of modern oncology (2013) (0)
- The impact of COVID-19 on population cancer screening programs in Australia: modelled evaluations for breast, bowel and cervical cancer (2022) (0)
- Abstract P5-14-08: The Impact of Immediate Breast Reconstruction on Surgical Complications and the Delivery of Adjuvant Chemotherapy: (2010) (0)
- 965The estimated impact of improved breast screening tests targeted at women with dense breasts (2021) (0)
- Abstract PD2-13: Benefits to breast screening beyond mortality reduction (2018) (0)
- Abstract P3-11-05: RANK ligand is a target for breast cancer prevention inBRCA1mutation carriers (2016) (0)
- Abstract P3-08-04: Survivorship care involving a nurse-led survivorship consultation, community support and shared care with primary practitioners (2013) (0)
- Abstract P4-11-02: Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk (2018) (0)
- Abstract P3-04-08: Genomic analysis of breast papillomas (2018) (0)
- Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma (2012) (0)
- Clinical medicine and culture: impressions of the first Australian exchange clinician to the NCCH. (1998) (0)
- Early Detection of Gastric Adenocarcinoma: The Key to Reduce or an Illusion? (1998) (0)
- Identification of Breast Cancer Survivors’ Side Effects and Supportive Care Needs (2018) (0)
- Abstract PD1-12: Identification of copy number alterations associated with the progression of high risk premalignant breast lesions to breast carcinoma (2018) (0)
- Early detection of gastric adenocarcinoma: the key to reduce mortality or an illusion? (1998) (0)
- Abstract P4-02-02: Outcomes of diagnostic surgical biopsy in a population-based mammographic screening program (2019) (0)
- Malignant breast disease and surgery (2019) (0)
- Abstract P3-04-06: Genomic analysis of cancers arising in breasts with different mammographic density (2018) (0)
- OP3 Are Victorian women interested in risk stratified breast screening? (2020) (0)
- A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia (2023) (0)
- Outcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience. (2019) (0)
- Abstract OT1-11-01: The PREDICT registry Australia: A prospective registry study to evaluate the clinical utility of the DCISionRT test on treatment decisions in patients with DCIS following breast conserving surgery (2022) (0)
- Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer (2013) (0)
- P199 Neoadjuvant systemic therapy for breast cancer: a survey of Australian and New Zealand specialists (2015) (0)
- Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result (2019) (0)
- Breast assessment and benign breast disease (2019) (0)
- Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk (2018) (0)
This paper list is powered by the following services:
Other Resources About Bruce Mann
What Schools Are Affiliated With Bruce Mann ?
Bruce Mann is affiliated with the following schools:
